Podocyte expression of nonmuscle myosin heavy chain-IIA decreases in idiopathic nephrotic syndrome, especially in focal segmental glomerulosclerosis

Nephrology Dialysis Transplantation

Volumn 28, Issue 12, 2013, Pages 2993-3003

  Miura, Kenichiro ^a   Kurihara, Hidetake ^b   Horita, Shigeru ^c   Chikamoto, Hiroko ^c   Hattori, Motoshi ^c   Harita, Yutaka ^a   Tsurumi, Haruko ^a   Kajiho, Yuko ^a   Sawada, Yoko ^d   Sasaki, Satoshi ^e   Igarashi, Takashi ^a   Kunishima, Shinji ^f   Sekine, Takashi ^d  

^a UNIVERSITY OF TOKYO   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^d TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

Author keywords

Focal segmental glomerulosclerosis; Myh9; Nonmuscle myosin heavy chain IIA; Podocyte; Primary process

Indexed keywords

ANTIBODY; MYOSIN IIA; MYOSIN IIB; NONMUSCULAR MYOSIN HEAVY CHAIN IIA ANTIBODY; PODOCALYXIN; PROTEIN ZO1; PUROMYCIN AMINONUCLEOSIDE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANAPHYLACTOID PURPURA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; CELLULAR DISTRIBUTION; CHILD; CHRONIC GLOMERULONEPHRITIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; FOCAL GLOMERULOSCLEROSIS; GLOMERULOPATHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOHISTOCHEMISTRY; KIDNEY TRANSPLANTATION; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; MINIMAL CHANGE GLOMERULONEPHRITIS; NEPHRITIS; NEPHROTIC SYNDROME; NONHUMAN; PODOCYTE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; SCHOOL CHILD; YOUNG ADULT;

FOCAL SEGMENTAL GLOMERULOSCLEROSIS; MYH9; NONMUSCLE MYOSIN HEAVY CHAIN-IIA; PODOCYTE; PRIMARY PROCESS;

ADOLESCENT; ADULT; ANIMALS; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; FEMALE; GLOMERULONEPHRITIS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; KIDNEY GLOMERULUS; MALE; MICROSCOPY, ELECTRON; MIDDLE AGED; MOLECULAR MOTOR PROTEINS; MYOSIN HEAVY CHAINS; PODOCYTES; PROTEINURIA; RATS; RATS, WISTAR;

EID: 84890040995     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft350     Document Type: Article

References (43)

1. Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet 2003; 362: 629-639
2. Boute N, Gribouval O, Roselli S et al. NPHS2, Encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 2000; 24: 349-354. Erratum in Nat Genet. 2000;25:125
3. Kaplan JM, Kim SH, North KN et al. Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet 2000; 24: 251-256
4. Winn MP, Conlon PJ, Lynn KL et al. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 2005; 308: 1801-1804
5. Hinkes B,Wiggins RC, Gbadegesin R et al. Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. Nat Genet 2006; 38: 1397-1405
6. Kopp JB, Smith MW, Nelson GW et al. MYH9 Is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008; 40: 1175-1184
7. Kao WH, Klag MJ, Meoni LA et al. Family investigation of nephropathy and diabetes research group: MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 2008; 40: 1185-1192
8. Genovese G, Friedman DJ, Ross MD et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329: 841-845
9. Friedman DJ, Kozlitina J, Genovese G et al. Population-based risk assessment of APOL1 on renal disease. J Am Soc Nephrol 2011; 22: 2098-2105
10. Kanji Z, Powe CE, Wenger JB et al. Genetic variation in APOL1 associates with younger age at hemodialysis initiation. J Am Soc Nephrol 2011; 22: 2091-2097
11. Reeves-Daniel AM, DePalma JA, Bleyer AJ et al. The APOL1 gene and allograft survival after kidney transplantation. Am J Transplant 2011; 11: 1025-1030
12. O'Seaghdha CM, Parekh RS, Hwang SJ et al. The MYH9/APOL1 region and chronic kidney disease in European-Americans. Hum Mol Genet 2011; 20: 2450-2456
13. Cooke JN, Bostrom MA, Hicks PJ et al. Polymorphisms in MYH9 are associated with diabetic nephropathy in European Americans. Nephrol Dial Transplant 2012; 27: 1505-1511
14. Heath KE, Campos-Barros A, Toren A et al. Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes. Am J Hum Genet 2001; 69: 1033-1045
15. SeriM, Pecci A, Di Bari F et al. MYH9-related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine (Baltimore) 2003; 82: 203-215
16. Kunishima S, Matsushita T, Kojima T et al. Identification of six novel MYH9 mutations and genotype-phenotype relationships in autosomal dominant macrothrombocytopenia with leukocyte inclusions. J Hum Genet 2001; 46: 722-729
17. Kopp JB. Glomerular pathology in autosomal dominant MYH9 spectrum disorders: what are the clues telling us about disease mechanism? Kidney Int 2010; 78: 130-133
18. Naito I, Nomura S, Inoue S et al. Normal distribution of collagen IV in renal basement membranes in Epstein's syndrome. J Clin Pathol 1997; 50: 919-922
19. Sekine T, Konno M, Sasaki S et al. Patients with Epstein-Fechtner syndromes owing to MYH9 R702 mutations develop progressive proteinuric renal disease. Kidney Int 2010; 78: 207-214
20. Zhang Y, Conti MA, Malide D et al. Mouse models of MYH9-related disease: mutations in nonmuscle myosin II-A. Blood 2012; 119: 238-250
21. Johnstone DB, Zhang J, George B et al. Podocyte-specific deletion of Myh9 encoding nonmuscle myosin heavy chain 2A predisposes mice to glomerulopathy. Mol Cell Biol 2011; 31: 2162-2170
22. Miller M, Bower E, Levitt P et al. Myosin II distribution in neurons is consistent with a role in growth cone motility but not synaptic vesicle mobilization. Neuron 1992; 8: 25-44
23. Kunishima S, Kojima T, Matsushita T et al. Mutations in the NMMHC-A gene cause autosomal dominant macrothrombocytopenia with leukocyte inclusions (May-Hegglin anomaly/Sebastian syndrome). Blood 2001; 97: 1147-1149
24. Matsushita T, Hayashi H, Kunishima S et al. Targeted disruption of mouse ortholog of the human MYH9 responsible for macrothrombocytopenia with different organ involvement: hematological, nephrological, and otological studies of heterozygous KO mice. Biochem Biophys Res Com 2004; 325: 1163-1171
25. Cheng XT, Hayashi K, Shirao T. Non-muscle myosin IIB-like immunoreactivity is present at the drebrin-binding cytoskeleton in neurons. Neurosci Res 2000; 36: 167-173
26. Harita Y, Kurihara H, Kosako H et al. Phosphorylation of nephrin triggers Ca2+ signaling by recruitment and activation of phospholipase C-gamma. J Biol Chem 2009; 284: 8951-8962
27. Harita Y, Kurihara H, Kosako H et al. Neph1, a component of the kidney slit diaphragm, is tyrosine-phosphorylated by the Src family tyrosine kinase and modulates intracellular signaling by binding to Grb2. J Biol Chem 2008; 283: 9177-9186
28. Kajiho Y, Harita Y, Kurihara H et al. SIRPα interacts with nephrin at the podocyte slit diaphragm. FEBS J 2012; 279: 3010-3021
29. Kurihara H, Sunagawa N, Kobayashi T et al. Monoclonal antibody P-31 recognizes a novel intermediate filament-associated protein (p250) in rat podocytes. Am J Physiol 1998; 274: F986-F997
30. Notoya M, Shinosaki T, Kobayashi T et al. Intussusceptive capillary growth is required for glomerular repair in rat Thy-1.1 nephritis. Kidney Int 2003; 63: 1365-1373
31. Tokuyasu KT. Use of poly(vinylpyrrolidone) and poly(vinyl alcohol) for cryoultramicrotomy. Histochem J 1989; 21: 163-171
32. Zou J, Yaoita E,Watanabe Y et al. Upregulation of nestin, vimentin, and desmin in rat podocytes in response to injury. Virchows Arch 2006; 448: 485-492
33. Wagrowska-Danilewicz M, Stasikowska O, Danilewicz M. Immunoexpression of podocyte-associated preteins in acquired human glomerulopathies with nephrotic syndrome. Pol J Pathol 2006; 57: 17-21
34. Patrakka J, Ruotsalainen V, Ketola I et al. Expression of nephrin in pediatric kidney diseases. J Am Soc Nephrol 2001; 12: 289-296
35. Hingorani SR, Finn LS, Kowalewska J et al. Expression of nephrin in acquired forms of nephrotic syndrome in childhood. Pediatr Nephrol 2004; 19: 300-305
36. Wernerson A, Duner F, Pettersson E et al. Altered ultrastructural distribution of nephrin in minimal change nephrotic syndrome. Nephrol Dial Transplant 2003; 18: 70-76
37. Guan N, Ding J, Zhang J et al. Expression of nephrin, podocin, alpha-actinin, and WT1 in children with nephrotic syndrome. Pediatr Nephrol. 2003; 18: 1122-1127
38. Koop K, Eikmans M, Baelde HJ et al. Expression of podocyteassociated molecules in acquired human kidney diseases. J Am Soc Nephrol 2003; 14: 2063-2071
39. Pippin JW, Brinkkoetter PT, Cormack-Aboud FC et al. Inducible rodent models of acquired podocyte diseases. Am J Physiol Renal Physiol 2009; 296: F213-F229
40. Arrondel C, Vodovar N, Knebelmann B et al. Expression of the nonmuscle myosin heavy chain IIA in the human kidney and screening for MYH9 mutations in Epstein and Fechtner syndromes. J Am Soc Nephrol 2002; 13: 65-74
41. Ghiggeri GM, Caridi G, Magrini U et al. Genetics, clinical and pathological features of glomerulonephritis associated with mutations of nonmuscle myosin IIA (Fechtner syndrome). Am J Kidney Dis 2003; 41: 95-104
42. Even-Ram S, Yamada KM.: Of mice and men: relevance of cellular and molecular characterizations of myosin IIA to MYH9-related human disease. Cell Adh Migr 2007; 1: 152-155
43. Babayeva S, Miller M, Zilber Y et al. Plasma from a case of recurrent idiopathic FSGS perturbs non-muscle myosin IIA (MYH9 protein) in human podocytes. Pediatr Nephrol 2011; 26: 1071-1081